Global Behcets Disease Market

Behcets Disease Comprehensive Study by Application (Men, Women, Others), Affected body part (Mouth, Skin, Genitals, Eyes, Joints, Blood Vessels, Digestive System, Brain), Treatment (Corticosteroids (Methylprednisolone, Prednisone, Dexamethasone), Immunosuppressive Agents (Azathioprine, Cyclophosphamide, Chlorambucil), Immunomodulators (Colchicine, Dapsone, Sulfasalazine)) Players and Region - Global Market Outlook to 2026

Behcets Disease Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Behcet disease is a disorder that affects multiple parts of the body, the common symptom complex of recurrent oral aphthous ulcers, genital ulcers, and uveitis. This disease is rare severely debilitating vasculitis, which typically manifests as a mucocutaneous disease with orogenital ulcers and skin lesions; however, the involvement of the musculoskeletal system, eye, nervous system, gastrointestinal tract, vascular beds, urogenital tract, and the cardio-pulmonary system can lead to significant morbidity and mortality. There is often a long delay between the onset of symptoms and diagnosis of BD because of the variable, and sometimes intermittent, symptoms, the need for exclusion of mimics, the lack of a specific blood test and marker for the disease and, sadly, a general lack of awareness of this condition.This growth is primarily driven by Rise In Incidences of Behcet's Disease Globally.

Major Players, such as Sienna Biopharmaceuticals (United States), Cell Medica (United Kingdom), Actelion (Switzerland), Abbott (United States), Novartis (Switzerland), Laboratoires Servier (France), AbbVie (United States), Celgene Corporation (United States), F. Hoffmann-La Roche (Switzerland) and Pfizer (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In May 2019, IntelGenx Corp. announced that the United States Patent and Trademark Office issued U.S. Patent 10,272,038 which is entitled as Film Dosage Form with Extended Release Mucoadhesive Particles. This patent covers the design and manufacturing of topical oral films for the local treatment of diseases of the oral mucosa using mucoadhesive particles.

Market Drivers
  • Rise In Incidences of Behcet's Disease Globally

Market Trend

Restraints
  • Lack Of Awareness Among Individuals And Healthcare Professionals Will Act As A Restraint For The Growth Of This Market.

Opportunities
Technological Advancements in Healthcare Industry and Increasing R&D Expenditure by the Government Will Aid In Creating Lucrative Opportunities

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Behcets Disease Study Sheds Light on
— The Behcets Disease Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Behcets Disease industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Behcets Disease industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Men
  • Women
  • Others
By Affected body part
  • Mouth
  • Skin
  • Genitals
  • Eyes
  • Joints
  • Blood Vessels
  • Digestive System
  • Brain

By Treatment
  • Corticosteroids (Methylprednisolone, Prednisone, Dexamethasone)
  • Immunosuppressive Agents (Azathioprine, Cyclophosphamide, Chlorambucil)
  • Immunomodulators (Colchicine, Dapsone, Sulfasalazine)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise In Incidences of Behcet's Disease Globally
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Behcets Disease, by Application, Affected body part, Treatment and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Behcets Disease (Value)
      • 5.2.1. Global Behcets Disease by: Application (Value)
        • 5.2.1.1. Men
        • 5.2.1.2. Women
        • 5.2.1.3. Others
      • 5.2.2. Global Behcets Disease by: Affected body part (Value)
        • 5.2.2.1. Mouth
        • 5.2.2.2. Skin
        • 5.2.2.3. Genitals
        • 5.2.2.4. Eyes
        • 5.2.2.5. Joints
        • 5.2.2.6. Blood Vessels
        • 5.2.2.7. Digestive System
        • 5.2.2.8. Brain
      • 5.2.3. Global Behcets Disease Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Behcets Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sienna Biopharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cell Medica (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Actelion (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Laboratoires Servier (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celgene Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Behcets Disease Sale, by Application, Affected body part, Treatment and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Behcets Disease (Value)
      • 7.2.1. Global Behcets Disease by: Application (Value)
        • 7.2.1.1. Men
        • 7.2.1.2. Women
        • 7.2.1.3. Others
      • 7.2.2. Global Behcets Disease by: Affected body part (Value)
        • 7.2.2.1. Mouth
        • 7.2.2.2. Skin
        • 7.2.2.3. Genitals
        • 7.2.2.4. Eyes
        • 7.2.2.5. Joints
        • 7.2.2.6. Blood Vessels
        • 7.2.2.7. Digestive System
        • 7.2.2.8. Brain
      • 7.2.3. Global Behcets Disease Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Behcets Disease: by Application(USD Million)
  • Table 2. Behcets Disease Men , by Region USD Million (2015-2020)
  • Table 3. Behcets Disease Women , by Region USD Million (2015-2020)
  • Table 4. Behcets Disease Others , by Region USD Million (2015-2020)
  • Table 5. Behcets Disease: by Affected body part(USD Million)
  • Table 6. Behcets Disease Mouth , by Region USD Million (2015-2020)
  • Table 7. Behcets Disease Skin , by Region USD Million (2015-2020)
  • Table 8. Behcets Disease Genitals , by Region USD Million (2015-2020)
  • Table 9. Behcets Disease Eyes , by Region USD Million (2015-2020)
  • Table 10. Behcets Disease Joints , by Region USD Million (2015-2020)
  • Table 11. Behcets Disease Blood Vessels , by Region USD Million (2015-2020)
  • Table 12. Behcets Disease Digestive System , by Region USD Million (2015-2020)
  • Table 13. Behcets Disease Brain , by Region USD Million (2015-2020)
  • Table 14. South America Behcets Disease, by Country USD Million (2015-2020)
  • Table 15. South America Behcets Disease, by Application USD Million (2015-2020)
  • Table 16. South America Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 17. South America Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 18. Brazil Behcets Disease, by Application USD Million (2015-2020)
  • Table 19. Brazil Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 20. Brazil Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 21. Argentina Behcets Disease, by Application USD Million (2015-2020)
  • Table 22. Argentina Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 23. Argentina Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 24. Rest of South America Behcets Disease, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 26. Rest of South America Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 27. Asia Pacific Behcets Disease, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Behcets Disease, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 30. Asia Pacific Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 31. China Behcets Disease, by Application USD Million (2015-2020)
  • Table 32. China Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 33. China Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 34. Japan Behcets Disease, by Application USD Million (2015-2020)
  • Table 35. Japan Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 36. Japan Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 37. India Behcets Disease, by Application USD Million (2015-2020)
  • Table 38. India Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 39. India Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 40. South Korea Behcets Disease, by Application USD Million (2015-2020)
  • Table 41. South Korea Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 42. South Korea Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 43. Taiwan Behcets Disease, by Application USD Million (2015-2020)
  • Table 44. Taiwan Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 45. Taiwan Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 46. Australia Behcets Disease, by Application USD Million (2015-2020)
  • Table 47. Australia Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 48. Australia Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Behcets Disease, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 52. Europe Behcets Disease, by Country USD Million (2015-2020)
  • Table 53. Europe Behcets Disease, by Application USD Million (2015-2020)
  • Table 54. Europe Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 55. Europe Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 56. Germany Behcets Disease, by Application USD Million (2015-2020)
  • Table 57. Germany Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 58. Germany Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 59. France Behcets Disease, by Application USD Million (2015-2020)
  • Table 60. France Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 61. France Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 62. Italy Behcets Disease, by Application USD Million (2015-2020)
  • Table 63. Italy Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 64. Italy Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 65. United Kingdom Behcets Disease, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 67. United Kingdom Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 68. Netherlands Behcets Disease, by Application USD Million (2015-2020)
  • Table 69. Netherlands Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 70. Netherlands Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 71. Rest of Europe Behcets Disease, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 73. Rest of Europe Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 74. MEA Behcets Disease, by Country USD Million (2015-2020)
  • Table 75. MEA Behcets Disease, by Application USD Million (2015-2020)
  • Table 76. MEA Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 77. MEA Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 78. Middle East Behcets Disease, by Application USD Million (2015-2020)
  • Table 79. Middle East Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 80. Middle East Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 81. Africa Behcets Disease, by Application USD Million (2015-2020)
  • Table 82. Africa Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 83. Africa Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 84. North America Behcets Disease, by Country USD Million (2015-2020)
  • Table 85. North America Behcets Disease, by Application USD Million (2015-2020)
  • Table 86. North America Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 87. North America Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 88. United States Behcets Disease, by Application USD Million (2015-2020)
  • Table 89. United States Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 90. United States Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 91. Canada Behcets Disease, by Application USD Million (2015-2020)
  • Table 92. Canada Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 93. Canada Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 94. Mexico Behcets Disease, by Application USD Million (2015-2020)
  • Table 95. Mexico Behcets Disease, by Affected body part USD Million (2015-2020)
  • Table 96. Mexico Behcets Disease, by Treatment USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Behcets Disease: by Application(USD Million)
  • Table 108. Behcets Disease Men , by Region USD Million (2021-2026)
  • Table 109. Behcets Disease Women , by Region USD Million (2021-2026)
  • Table 110. Behcets Disease Others , by Region USD Million (2021-2026)
  • Table 111. Behcets Disease: by Affected body part(USD Million)
  • Table 112. Behcets Disease Mouth , by Region USD Million (2021-2026)
  • Table 113. Behcets Disease Skin , by Region USD Million (2021-2026)
  • Table 114. Behcets Disease Genitals , by Region USD Million (2021-2026)
  • Table 115. Behcets Disease Eyes , by Region USD Million (2021-2026)
  • Table 116. Behcets Disease Joints , by Region USD Million (2021-2026)
  • Table 117. Behcets Disease Blood Vessels , by Region USD Million (2021-2026)
  • Table 118. Behcets Disease Digestive System , by Region USD Million (2021-2026)
  • Table 119. Behcets Disease Brain , by Region USD Million (2021-2026)
  • Table 120. South America Behcets Disease, by Country USD Million (2021-2026)
  • Table 121. South America Behcets Disease, by Application USD Million (2021-2026)
  • Table 122. South America Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 123. South America Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 124. Brazil Behcets Disease, by Application USD Million (2021-2026)
  • Table 125. Brazil Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 126. Brazil Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 127. Argentina Behcets Disease, by Application USD Million (2021-2026)
  • Table 128. Argentina Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 129. Argentina Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 130. Rest of South America Behcets Disease, by Application USD Million (2021-2026)
  • Table 131. Rest of South America Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 132. Rest of South America Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 133. Asia Pacific Behcets Disease, by Country USD Million (2021-2026)
  • Table 134. Asia Pacific Behcets Disease, by Application USD Million (2021-2026)
  • Table 135. Asia Pacific Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 136. Asia Pacific Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 137. China Behcets Disease, by Application USD Million (2021-2026)
  • Table 138. China Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 139. China Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 140. Japan Behcets Disease, by Application USD Million (2021-2026)
  • Table 141. Japan Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 142. Japan Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 143. India Behcets Disease, by Application USD Million (2021-2026)
  • Table 144. India Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 145. India Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 146. South Korea Behcets Disease, by Application USD Million (2021-2026)
  • Table 147. South Korea Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 148. South Korea Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 149. Taiwan Behcets Disease, by Application USD Million (2021-2026)
  • Table 150. Taiwan Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 151. Taiwan Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 152. Australia Behcets Disease, by Application USD Million (2021-2026)
  • Table 153. Australia Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 154. Australia Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Behcets Disease, by Application USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 158. Europe Behcets Disease, by Country USD Million (2021-2026)
  • Table 159. Europe Behcets Disease, by Application USD Million (2021-2026)
  • Table 160. Europe Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 161. Europe Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 162. Germany Behcets Disease, by Application USD Million (2021-2026)
  • Table 163. Germany Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 164. Germany Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 165. France Behcets Disease, by Application USD Million (2021-2026)
  • Table 166. France Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 167. France Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 168. Italy Behcets Disease, by Application USD Million (2021-2026)
  • Table 169. Italy Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 170. Italy Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 171. United Kingdom Behcets Disease, by Application USD Million (2021-2026)
  • Table 172. United Kingdom Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 173. United Kingdom Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 174. Netherlands Behcets Disease, by Application USD Million (2021-2026)
  • Table 175. Netherlands Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 176. Netherlands Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 177. Rest of Europe Behcets Disease, by Application USD Million (2021-2026)
  • Table 178. Rest of Europe Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 179. Rest of Europe Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 180. MEA Behcets Disease, by Country USD Million (2021-2026)
  • Table 181. MEA Behcets Disease, by Application USD Million (2021-2026)
  • Table 182. MEA Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 183. MEA Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 184. Middle East Behcets Disease, by Application USD Million (2021-2026)
  • Table 185. Middle East Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 186. Middle East Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 187. Africa Behcets Disease, by Application USD Million (2021-2026)
  • Table 188. Africa Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 189. Africa Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 190. North America Behcets Disease, by Country USD Million (2021-2026)
  • Table 191. North America Behcets Disease, by Application USD Million (2021-2026)
  • Table 192. North America Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 193. North America Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 194. United States Behcets Disease, by Application USD Million (2021-2026)
  • Table 195. United States Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 196. United States Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 197. Canada Behcets Disease, by Application USD Million (2021-2026)
  • Table 198. Canada Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 199. Canada Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 200. Mexico Behcets Disease, by Application USD Million (2021-2026)
  • Table 201. Mexico Behcets Disease, by Affected body part USD Million (2021-2026)
  • Table 202. Mexico Behcets Disease, by Treatment USD Million (2021-2026)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Behcets Disease: by Application USD Million (2015-2020)
  • Figure 5. Global Behcets Disease: by Affected body part USD Million (2015-2020)
  • Figure 6. South America Behcets Disease Share (%), by Country
  • Figure 7. Asia Pacific Behcets Disease Share (%), by Country
  • Figure 8. Europe Behcets Disease Share (%), by Country
  • Figure 9. MEA Behcets Disease Share (%), by Country
  • Figure 10. North America Behcets Disease Share (%), by Country
  • Figure 11. Global Behcets Disease share by Players 2020 (%)
  • Figure 12. Global Behcets Disease share by Players (Top 3) 2020(%)
  • Figure 13. Global Behcets Disease share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Sienna Biopharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 16. Sienna Biopharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 17. Cell Medica (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Cell Medica (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Actelion (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Actelion (Switzerland) Revenue: by Geography 2020
  • Figure 21. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 22. Abbott (United States) Revenue: by Geography 2020
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 25. Laboratoires Servier (France) Revenue, Net Income and Gross profit
  • Figure 26. Laboratoires Servier (France) Revenue: by Geography 2020
  • Figure 27. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie (United States) Revenue: by Geography 2020
  • Figure 29. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 31. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2020
  • Figure 33. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer (United States) Revenue: by Geography 2020
  • Figure 35. Global Behcets Disease: by Application USD Million (2021-2026)
  • Figure 36. Global Behcets Disease: by Affected body part USD Million (2021-2026)
  • Figure 37. South America Behcets Disease Share (%), by Country
  • Figure 38. Asia Pacific Behcets Disease Share (%), by Country
  • Figure 39. Europe Behcets Disease Share (%), by Country
  • Figure 40. MEA Behcets Disease Share (%), by Country
  • Figure 41. North America Behcets Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sienna Biopharmaceuticals (United States)
  • Cell Medica (United Kingdom)
  • Actelion (Switzerland)
  • Abbott (United States)
  • Novartis (Switzerland)
  • Laboratoires Servier (France)
  • AbbVie (United States)
  • Celgene Corporation (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • Pfizer (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 233 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Behcets Disease Market Quantitative research analysis
Global Behcets Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Behcets Disease Market are Sienna Biopharmaceuticals (United States), Cell Medica (United Kingdom), Actelion (Switzerland), Abbott (United States), Novartis (Switzerland), Laboratoires Servier (France), AbbVie (United States), Celgene Corporation (United States), F. Hoffmann-La Roche (Switzerland) and Pfizer (United States) etc.
Behcet disease is a disorder that affects multiple parts of the body, the common symptom complex of recurrent oral aphthous ulcers, genital ulcers, and uveitis. This disease is rare severely debilitating vasculitis, which typically manifests as a mucocutaneous disease with orogenital ulcers and skin lesions; however, the involvement of the musculoskeletal system, eye, nervous system, gastrointestinal tract, vascular beds, urogenital tract, and the cardio-pulmonary system can lead to significant morbidity and mortality. There is often a long delay between the onset of symptoms and diagnosis of BD because of the variable, and sometimes intermittent, symptoms, the need for exclusion of mimics, the lack of a specific blood test and marker for the disease and, sadly, a general lack of awareness of this condition.

Know More About Global Behcets Disease Market Report?

Have a Query? Click Here

Other Related Reports

Montelukast Intermediate Comprehensive Study by Application (Asthma, Allergic rhinitis, Bronchospasm, Urticaria) Players and Region - Global Market Outlook to 2030
$ 3500
Oral Thrush Comprehensive Study by Type (Pseudomembranous, Erythematous, Hyperplastic, Others), Application (Hospitals, Clinics), Diagnosis Methods (Examination, Biopsy, Endoscopy, Others.), Treatmen...
$ 3450
Treatment for Communicable Diseases Comprehensive Study by Type (Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others), Vaccines), Application (Hospital, Clinic, Other), Diseases...
$ 3750
Injectable Anti-Wrinkle Comprehensive Study by Type (Muscle Relaxants (Botox Injections, Others), Synthetic Wrinkle Fillers (Sculptra, Radiesse, Silicone), Autologous Wrinkle Fillers, Muscle Relaxant...
$ 3750
Unna Boot Comprehensive Study by Application (Venous Leg Ulcers, Lymphedema, Eczema), Raw Material (Zinc Oxide, Zinc, Calamine), Distribution Channel (Offline Retail, Online Retail) Players and Regi...
$ 3500
RNA Based Therapeutics Comprehensive Study by Application (Cardiovascular, Kidney Diseases, Oncology, Infectious Diseases, Metabolic Disorders, Others), Technology (Inhibition, Microarrays, Labeling,...
$ 3650